A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

New England Journal of Medicine

Volumn 348, Issue 13, 2003, Pages 1201-1214

  Cools, Jan ^a,m   DeAngelo, Daniel J ^b   Gotlib, Jason ^c   Stover, Elizabeth H ^a   Legare, Robert D ^d,e   Cortes, Jorges ^f   Kutok, Jeffrey ^a   Clark, Jennifer ^a,b   Galinsky, Ilene ^b   Griffin, James D ^b   Cross, Nicholas C P ^g   Tefferi, Ayalew ^h   Malone, James ^c   Alam, Rafeul ⁱ   Schrier, Stanley L ^c   Schmid, Janet ^j   Rose, Michal ^k   Vandenberghe, Peter ^l   Verhoef, Gregor ^l   Boogaerts, Marc ^l   Wlodarska, Iwona ⁿ   Kantarjian, Hagop ^f   Marynen, Peter ^m   Coutre, Steven E ^c   Stone, Richard ^b   Gilliland, D Gary ^a,b,o   more..

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BROWN UNIVERSITY   (United States)

^e Westerly Hospital   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g WESSEX REGIONAL GENETICS LABORATORY   (United Kingdom)

^h MAYO CLINIC   (United States)

ⁱ NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^j TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^m DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

ⁿ Center for Human Genetics   (Belgium)

^o HARVARD INSTITUTES OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FIP1 L1 PROTEIN; HYBRID PROTEIN; IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN TYROSINE KINASE; STEM CELL FACTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHROMOSOME 4Q; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CLINICAL ARTICLE; DRUG TARGETING; EOSINOPHILIA; FEMALE; FUSION GENE; GENE MUTATION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; HYPEREOSINOPHILIC SYNDROME; MALE; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; RELAPSE; TREATMENT OUTCOME;

ADULT; BASE SEQUENCE; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 4; ENZYME INHIBITORS; FEMALE; HUMANS; HYPEREOSINOPHILIC SYNDROME; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RECOMBINATION, GENETIC; REMISSION INDUCTION;

EID: 0344987881     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa025217     Document Type: Article

References (28)

1. Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 1975;54:1-27.
2. Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood 1994; 83:2759-79.
3. Luppi M, Marasca R, Morselli M, Barozzi P, Torelli G. Clonal nature of hypereosinophilic syndrome. Blood 1994;84:349-50.
4. Chang HW, Leong KH, Koh DR, Lee SH. Clonality of isolated eosinophils in the hypereosinophilic syndrome. Blood 1999; 93:1651-7.
5. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 2002;359:1577-8.
6. Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996; 56:100-4.
7. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344: 1038-42. [Erratum, N Engl J Med 2001;345: 232.]
8. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344: 1031-7.
9. Carroll M, Ohno-Jones S, Tamura S, et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 1997;90:4947-52.
10. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295:139-45.
11. Tuveson DA, Willis NA, Jacks T, et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 2001; 20:5054-8.
12. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. Engl J Med 2002;347:472-80.
13. Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002;347:481-7.
14. Dierlamm J, Wlodarska I, Michaux L, et al. Successful use of the same slide for consecutive fluorescence in situ hybridization experiments. Genes Chromosomes Cancer 1996;16:261-4.
15. Cools J, Bilhou-Nabera C, Wlodarska I, et al. Fusion of a novel gene, BTL, to ETV6 in acute myeloid leukemias with a t(4;12) (q11-q12;p13). Blood 1999;94:1820-4.
16. Willis TG, Jadayel DM, Coignet LJ, et al. Rapid molecular cloning of rearrangements of the IGHJ locus using long-distance inverse polymerase chain reaction. Blood 1997;90: 2456-64.
17. Schwaller J, Frantsve J, Aster J, et al. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion gene. EMBO J 1998;17: 5321-33.
18. Cools J, Mentens N, Odero MD, et al. Evidence for position effects as a variant ETV6-mediated leukemogenic mechanism in myeloid leukemias with a t(4;12) (q11q12;p13) or t(5;12)(q31;p13). Blood 2002; 99:1776-84.
19. Kawagishi J, Kumabe T, Yoshimoto T, Yamamoto T. Structure, organization, and transcription units of the human alphaplatelet-derived growth factor receptor gene, PDGFRA. Genomics 1995;30:224-32.
20. Preker PJ, Lingner J, Minvielle-Sebastia L, Keller W. The FIP1 gene encodes a component of a yeast pre-mRNA polyadenylation factor that directly interacts with poly(A) polymerase. Cell 1995;81:379-89.
21. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-80.
22. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2:117-25.
23. Roumiantsev S, Shah NP, Gorre ME, et al. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Ablkinase domain P-loop. Proc Natl Acad Sci U S A 2002;99: 10700-5.
24. de Klein A, van Kessel AG, Grosveld G, et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1982;300: 765-7.
25. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994;77:307-16.
26. Ross TS, Bernard OA, Berger R, Gilliland DG. Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukemia with t(5;7) (q33;q11.2). Blood 1998;91:4419-26.
27. Peeters P, Raynaud SD, Cools J, et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 1997;90:2535-40.
28. Schwaller J, Anastasiadou E, Cain D, et al. H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor beta gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22). Blood 2001;97: 3910-8.